Shapiro Eugene D
Departments of Pediatrics, Epidemiology of Microbial Diseases and Investigative Medicine, Yale University Schools of Medicine and of Public Health and Graduate School of Arts and Sciences New Haven, CT USA.
F1000Prime Rep. 2015 Jan 5;7:11. doi: 10.12703/P7-11. eCollection 2015.
Whether or not Borrelia burgdorferi can persist after conventional treatment with antimicrobials has been a very controversial issue. Two recent studies took different approaches to try to answer this question. In one, investigators showed that, in each of 22 instances in 17 patients with two consecutive episodes of culture-proved erythema migrans, the strains of B. burgdorferi were different based on their genotypes. This indicated that the repeat episodes were due to new infections rather than recrudescence of the original infection. In another study, in which persistence of B. burgdorferi was assessed by using xenodiagnosis, no viable B. burgdorferi were cultured from ticks fed on any of the patients. There continues to be no evidence that viable B. burgdorferi persist in humans after conventional treatment with antimicrobials.
伯氏疏螺旋体在接受常规抗菌治疗后是否能够持续存在一直是一个极具争议的问题。最近的两项研究采用了不同方法试图回答这个问题。在其中一项研究中，研究人员表明，在17例有两次连续培养证实的游走性红斑发作的患者的22个病例中，基于基因型，每一例的伯氏疏螺旋体菌株都不同。这表明反复发作出自新感染而非原感染的复发。在另一项通过异种接种法评估伯氏疏螺旋体持续性的研究中，没有从叮咬任何患者的蜱中培养出存活的伯氏疏螺旋体。目前仍然没有证据表明，伯氏疏螺旋体在接受常规抗菌治疗后能在人体内持续存在。
